Investment Bank Updates Rating for Swedish Orphan Bio PT
- ByInvesting.com-
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Swedish Orphan Biovitrum AB (SOBIV)
241.30
+3.50(+1.47%)
- Volume:284,792
- Bid/Ask:0.00/0.00
- Day's Range:238.00 - 241.40
SOBIV Overview
- Prev. Close
- 237.8
- Day's Range
- 238-241.4
- Revenue
- 16.79B
- Open
- 238.5
- 52 wk Range
- 166.5-245.4
- EPS
- 8.52
- Volume
- 284,792
- Market Cap
- 71.36B
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 643,469
- P/E Ratio
- 25.76
- Beta
- 0.398
- 1-Year Change
- 30.73%
- Shares Outstanding
- 295,855,926
- Next Earnings Date
- Oct 27, 2022
What is your sentiment on Swedish Orphan Biovitrum?
or
Vote to see community's results!
Swedish Orphan Biovitrum AB News
- European Stocks Calm; Payrolls and ECB Stimulus in Focus
- ByInvesting.com-
By Peter NurseInvesting.com -- European stock markets traded largely unchanged Thursday, with investors displaying caution ahead of Friday’s key U.S. payrolls release while...
- European shares jump on China trade data, coronavirus hopes
- ByReuters-
(Reuters) - European shares rose on Tuesday after a strong rally last week, as better-than-expected trade data from China added to relief from early signs that sweeping lockdown...
Swedish Orphan Biovitrum AB Analysis
- Exelixis Prepares For ASCO 2013, Stock Stays Rangebound
One of the biopharmaceutical companies that has been lagging the stellar performance of its peers is Exelixis (EXEL), developer of the compound cabozantinib. Cabo, which was FDA...
Swedish Orphan Biovitrum AB Company Profile
Swedish Orphan Biovitrum AB Company Profile
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.44 | 0.45 | 0.44 | 0.00 | +0.96% | 125.91K | NASDAQ | |||
| 59.49 | 59.89 | 59.16 | -0.26 | -0.44% | 758.67K | NYSE | |||
| 48.58 | 49.52 | 48.38 | -0.69 | -1.40% | 18.48M | NYSE | |||
| 150.00 | 158.51 | 148.26 | -8.00 | -5.06% | 6.91M | NASDAQ | |||
| 18.55 | 20.81 | 16.16 | -4.53 | -19.63% | 136.95M | NASDAQ | |||
| 120.86 | 121.68 | 119.56 | +0.54 | +0.45% | 15.38M | NASDAQ | |||
| 166.77 | 168.30 | 165.93 | -0.81 | -0.48% | 8.30M | NYSE | |||
| 139.07 | 139.12 | 137.75 | +1.28 | +0.93% | 3.16M | NYSE | |||
| 100.44 | 101.07 | 96.73 | +2.17 | +2.21% | 75.87M | NASDAQ | |||
| 22.31 | 22.41 | 22.25 | -0.01 | -0.04% | 4.75M | NYSE | |||
| 26.47 | 33.33 | 25.12 | +0.75 | +2.92% | 19.25M | NASDAQ | |||
| 9.62 | 9.84 | 9.34 | -0.17 | -1.69% | 6.88M | NYSE | |||
| 53.55 | 53.72 | 53.04 | -0.21 | -0.39% | 10.31M | NYSE | |||
| 1.80 | 1.97 | 1.40 | +0.400 | +28.57% | 875.91K | NASDAQ | |||
| 24.56 | 24.63 | 24.50 | -0.03 | -0.12% | 12.72K | NASDAQ |